ALX Oncology Holdings Income Taxes 2019-2025 | ALXO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ALX Oncology Holdings income taxes from 2019 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ALX Oncology Holdings income taxes from 2019 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.8B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$140.6B
Vertex Pharmaceuticals (VRTX)	$118.3B
Bristol Myers Squibb (BMY)	$96.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$76.5B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$36.4B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.8B
Insmed (INSM)	$19.3B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$17.4B
Genmab (GNMSF)	$15.2B
Genmab (GMAB)	$14.8B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.1B
Exelixis (EXEL)	$12.1B
QIAGEN (QGEN)	$11.3B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.6B